Author | Lightnews

DRUGDOCS® @drugdocs.bsky.social · 3d

JAMA+ Women’s Health, a new hub for sex-specific evidence in every specialty, has launched!
At DRUGDOCS®, we believe data transparency fuels better decisions and it’s why our platform includes sex distribution data for every RCT, supporting transparency and equity in health research. drugdocs.com

DRUGDOCS® @drugdocs.bsky.social · 3d

On World Psoriasis Day, we join the National Psoriasis Foundation to raise awareness of psoriatic disease and its links to conditions like heart disease & diabetes. Take the first steps toward protecting your health @ www.psoriasis.org/world-psoriasis-day

World Psoriasis Day

Get ready for October 29 by learning about psoriasis and connecting with people who truly understand you.

www.psoriasis.org

DRUGDOCS® @drugdocs.bsky.social · 10d

The FDA has approved Jascayd® (nerandomilast tablets), the first new treatment in mover than 10 years for idiopathic pulmonary fibrosis. Jascayd slowed lung function decline in trials, offering new hope for this serious, progressive disease.

🔬 Find the clinical data at DRUGDOCS.

DRUGDOCS | Jascayd®

drugdocs.com

DRUGDOCS® @drugdocs.bsky.social · 12d

FDA approves the Elecsys blood test to aid Alzheimer’s diagnosis. The test helps rule out the disease with 97.9% accuracy and may increase access to treatments like Leqembi and Kisunla.

📖 Read more below.

🔬 Explore the clinical data for Alzheimer’s drugs at DRUGDOCS: drugdocs.com/search/Alzhe...

www.reuters.com

DRUGDOCS® @drugdocs.bsky.social · 12d

It's World Evidence-Based Health Care Day!

At DRUGDOCS®, the importance of using high-quality evidence to guide decisions that improve health outcomes is central to our work.

We’re proud to support this mission because informed prescribing starts with trusted information.

🔗 worldebhcday.org

DRUGDOCS® @drugdocs.bsky.social · 16d

New FDA approval: Palsonify (paltusotine) for acromegaly in adults who cannot undergo, or haven’t respond to, surgery.
56% achieved biochemical control in trials, a promising oral option for this rare disorder.
🔍Find the clinical data at drugdocs.com/drug/Palsoni...

#FDA #Acromegaly

DRUGDOCS® @drugdocs.bsky.social · 18d

October marks Breast Cancer Awareness Month 🌸

This year’s focus at the #Global Breast Cancer Initiative: awareness, early detection, equitable access, and honoring those impacted.

Let’s turn awareness into action.

Find more information and how to get involved here: www.who.int/initiatives/...

The Global Breast Cancer Initiative

The World Health Organization’s Global Breast Cancer Initiative (GBCI), established in 2021, brings together stakeholders from around the world and across sectors with the joint goal of reducing globa...

www.who.int

DRUGDOCS® @drugdocs.bsky.social · 25d

FDA approves Vizz for presbyopia, a new use for an old glaucoma drug.
In clinical trials, Vizz was shown to improve near vision within 30 mins and lasts up to 10 hrs without affecting distance vision. A fresh option for millions dealing with age-related vision loss.
📖 Read more below.

FDA grants first US approval for decades-old eye drug

Discover the world’s best science and medicine | Nature.com

www.nature.com

DRUGDOCS® @drugdocs.bsky.social · 26d

🔍 Top 3 most searched drugs on DRUGDOCS in September:

1️⃣ Tonmya – 1st non-opioid FDA-approved treatment for fibromyalgia since 2007
2️⃣ Harvoni – Antiviral with high cure rates for hepatitis C
3️⃣ Selarsdi – Biologic for plaque psoriasis and psoriatic arthritis

📖 Find the evidence @ drugdocs.com

DRUGDOCS® @drugdocs.bsky.social · Oct 3

Zolymbus (bimatoprost 0.01% gel) by Thea Pharma is now FDA-approved!
📉 Equal IOP-lowering to preserved drops
🧴 Preservative-free
✅ Better tolerability
A promising new option for glaucoma patients needing long-term therapy.
#Zolymbus #Glaucoma #FDA

DRUGDOCS® @drugdocs.bsky.social · Oct 2

FDA has approved Forzinity for Barth syndrome, the first-ever treatment for this rare mitochondrial disease.
Approval is based on improved leg muscle strength, offering new hope for patients.
📖 Clinical evidence at @DRUGDOCS drugdocs.com/drug/Forzinity
🔗 Read more here: www.fda.gov/news-events/...

DRUGDOCS® @drugdocs.bsky.social · Oct 1

INLEXZO, the first intravesical gemcitabine system for Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer, has been approved. Trials show an 82% CR.

A new option for bladder cancer patients seeking to avoid radical cystectomy.

📊 Find the clinical data at drugdocs.com

U.S. FDA approval of INLEXZO™ (gemcitabine intravesical system) set to transform how certain bladder cancers are treated

Johnson Johnson (NYSE:JNJ) announced today the U.S. Food and Drug Administration (FDA) approved INLEXZO™ (gemcitabine intravesical system), a new, potentially practice-changing approach for treating ...

www.investor.jnj.com

DRUGDOCS® @drugdocs.bsky.social · Sep 23

📢 Merck’s Capvaxive, built for seniors, is proving effective in kids too.
✔️ Strong immune response in 21 serotypes
✔️ Superior to Pneumovax in unique serotypes
✔️ Favorable safety profile

🧪 Follow @DRUGDOCS for the clinical data when it’s approved in children and adolescents.

Despite being designed for seniors, Merck's pneumococcal shot shows potential in children

Approved 15 months ago as a pneumococcal disease vaccine for adults—and billed as the first shot designed for seniors—Merck’s Capvaxive now has data

www.fiercepharma.com

1

DRUGDOCS® @drugdocs.bsky.social · Sep 19

Big news in rare disease tx: The FDA has approved Papzimeos, the 1st immunotherapy for recurrent respiratory papillomatosis. This HPV-driven condition requires repeated surgeries. Now, >50% of trial patients were surgery-free for a year. Find the clinical evidence for Papzimeos @ DRUGDOCS.com

DRUGDOCS® @drugdocs.bsky.social · Sep 12

FDA approves Tonmya, the first new fibromyalgia treatment in over 16 years. Clinical trials showed reduced pain and improved sleep in nearly 1,000 patients.

📊 Find the clinical evidence at @DRUGDOCS: drugdocs.com/drug/Tonmya

🔗 Read more: www.fiercepharma.com/pharma/tonix...

DRUGDOCS® @drugdocs.bsky.social · Sep 10

September is Childhood Cancer Awareness month. 💛 Here is some positive research news for kids undergoing treatment. A new drug, briquilimab, may let stem cell transplant patients skip chemotherapy & radiation.
An early trial in children showed near 100% donor cell success, w/out major side effects.

Irradiation- and busulfan-free stem cell transplantation in Fanconi anemia using an anti-CD117 antibody: a phase 1b trial - Nature Medicine

In a phase 1b trial in three patients with Fanconi anemia, an irradiation- and busulfan-free conditioning regimen containing an anti-CD117 antibody, combined with T cell- and B cell-depleted haploiden...

www.nature.com

1

DRUGDOCS® @drugdocs.bsky.social · Sep 8

FDA launches Rare Disease Evidence Principles (RDEP), creating clearer, faster, and more flexible approval pathways for drug development for rare diseases with very small patient populations and high unmet need.

📖 Read more about the RDEP here: www.fda.gov/industry/fda...

CDER/CBER Rare Disease Evidence Principles (RDEP)

A proposed process to facilitate the approval of drugs to treat rare diseases

www.fda.gov

DRUGDOCS® @drugdocs.bsky.social · Sep 5

FDA grants accelerated approval to Wegovy for adults with metabolic dysfunction-associated steatohepatitis (MASH) and liver fibrosis (F2–F3).
📊 In the key trial, 63% achieved MASH resolution without worsening fibrosis (vs. 34% placebo)
🔎 Find the clinical evidence: drugdocs.com/drug/Wegovyh...

DRUGDOCS® @drugdocs.bsky.social · Sep 4

📈 Trending on DRUGDOCS® in August 2025:
1️⃣ Zegfrovy® – oral EGFR exon 20 inhibitor for advanced NSCLC
2️⃣ Brinsupri® – the first FDA-approved DPP1 inhibitor for bronchiectasis
3️⃣ Tyenne® – IL-6 blocker for RA, GCA, and juvenile idiopathic arthritis
🔍 Discover the science at DRUGDOCS® → drugdocs.com

DRUGDOCS® @drugdocs.bsky.social · Aug 26

Mayo Clinic treated the 1st U.S. patient with a novel alpha-emitting radiopharmaceutical therapy for advanced breast cancer. Using actinium-225, the trial explores powerful next-generation targeted radiation.

Read more: newsnetwork.mayoclinic.org/discussion/m...

#BreastCancerResearch #Oncology

DRUGDOCS® @drugdocs.bsky.social · Aug 21

Brinsupri achieves FDA approval as the 1st treatment for non-cystic fibrosis bronchiectasis. It also launches the novel DPP1 inhibitor class, blocking enzymes that fuel harmful lung inflammation. Big news for chronic lung disease.

💊 Find the clinical evidence @DrugDocs: drugdocs.com/drug/Brinsupri

1

DRUGDOCS® @drugdocs.bsky.social · Aug 18

It’s World Breast Cancer Research Day, a day created to amplify the ongoing need for research toward a cure.

1 in 8 women and 1 in 833 men will be diagnosed during their lifetime. Let’s keep funding and supporting the science that will lead to a cure. 💗

#WorldBreastCancerResearchDay

DRUGDOCS® @drugdocs.bsky.social · Aug 14

New NSCLC approval: FDA clears Zegfrovy (sunvozertinib) for EGFR exon 20+ disease after progression on platinum chemotherapy.

Key findings from the WU-KONG1B study:
✔️ 46% overall response rate
✔️ Median duration of response: 11.1 months

Explore the evidence on DRUGDOCS®: drugdocs.com/drug/Zegfrovy

DRUGDOCS® @drugdocs.bsky.social · Aug 12

It’s Psoriasis Awareness Month! Psoriasis affects 125 million people globally, with serious comorbidities such as cardiovascular disease and depression.

Explore the clinical evidence for 18 approved treatments on DRUGDOCS® and stay informed to support better care: drugdocs.com/search/psoriasis

DRUGDOCS® @drugdocs.bsky.social · Aug 8

FDA approves Sephience for phenylketonuria (PKU), a rare genetic metabolic disorder.
In trials, the drug cut phenylalanine levels by 63% on average, offering new hope for patients managing lifelong dietary restrictions.
💊Explore the clinical evidence for Sephience at drugdocs.com/drug/Sephience